Immuno-regulation of GI nematode infection
胃肠道线虫感染的免疫调节
基本信息
- 批准号:7388169
- 负责人:
- 金额:$ 36.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-05-01 至 2009-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAnimalsBiological ModelsCell Differentiation processCell physiologyChronicDefectDendritic CellsDevelopmentEpithelial CellsExposure toGastrointestinal tract structureGerm-FreeGoalsGoblet CellsHelminthsHumanImmuneImmune responseImmune systemImmunityIn VitroInfectionInterferonsInterleukin-12Interleukin-13Interleukin-18Interleukin-4Interleukin-6InterventionIntestinesMediatingModelingMolecularMusNatural ImmunityNematodaNematode infectionsParasitesPathway interactionsPopulationProductionProteinsRegulationResearch PersonnelResistance to infectionRoleSignal TransductionSoilSystemT-Cell ActivationT-Cell ReceptorTestingTh2 CellsTransgenic OrganismsTrichurisTumor Necrosis Factor-alphaTumor Necrosis Factorsbasecell typecytokinedesigngastrointestinalhuman TNF proteinin vivoinsightnovelpathogenresponsetool
项目摘要
An estimated 2 billion people world-wide are infected with soil transmitted helminth parasites, with an estimated 300 million people suffering severe infections. The long term goals of this proposal are to gain a better understanding of the immuno-regulatory mechanisms that govern the initiation, regulation, and effector responses following gastrointestinal (GI) nematode infection. Trichuris muris is a natural GI nematode of mice and provides an immunologically well-defined model of human infection. Previous studies have shown that T helper type 1 (Thl) responses promote chronic infection, while Th2 responses are required for host protective immunity. However, the cellular and molecular mechanisms that control how T. muris is recognized by the innate immune system and how Th2 cytokines mediate expulsion of
infection are unknown. Preliminary studies identified a critical role for NF-kappaB1 activation in immunity to T. muds. It is hypothesized that NF-kappaB1 regulates three novel pathways required for resistance to infection:
(i) intestinal epithelial cells (IEC) activation; (ii) dendritic cell (DC) responses; and (iii) expression of RELMb, a novel immune effector molecule required for expulsion of GI nematodes. The requirements for
these pathways in immunity to T. muds infection will be tested. First, the role of IEC and DC in innate recognition of T. muris and production of proinflammatory cytokines will be tested using either genetically manipulated animal hosts in which IEC function is specifically impaired, or the adoptive transfer of purified DC populations. Preliminary studies also identified a novel NF-kappaBl-dependent immune effector molecule, RELMb, that mediates expulsion of GI nematode infection. The factors that regulate expression of RELMb and mechanisms through which worms are expelled will be defined. Defining these pathways will provide
new insights into the regulation of innate and adaptive Th2 responses in the GI tract and offer novel targets to manipulate anti-nematode responses.
据估计,全世界有20亿人感染了土壤传播的蠕虫寄生虫,其中估计有3亿人遭受严重感染。这项建议的长期目标是更好地了解免疫调节机制,这些机制控制着胃肠道线虫感染后的启动、调节和效应反应。毛滴虫是一种天然的小鼠胃肠道线虫,为人类感染提供了一种免疫学上明确的模型。以前的研究表明,T辅助1型(THL)应答促进慢性感染,而Th2应答是宿主保护性免疫所必需的。然而,控制T细胞如何被先天性免疫系统识别的细胞和分子机制,以及Th2细胞因子如何介导T细胞的排出
感染是未知的。初步研究表明,核因子-kappaB1的激活在弓形虫免疫中起着关键作用。据推测,核因子-kappaB1调节三个新的抗感染途径:
(I)肠上皮细胞(IEC)的激活;(Ii)树突状细胞(DC)的反应;以及(Iii)RELMb的表达,RELMb是一种新的免疫效应分子,需要驱逐GI线虫。对以下各项的要求
我们将测试这些途径对毛滴虫感染的免疫力。首先,IEC和DC在T.Muris的先天识别和促炎细胞因子产生中的作用将通过使用IEC功能特别受损的基因操纵的动物宿主或通过过继转移纯化的DC群体来测试。初步研究还发现了一种新的依赖于NF-kappaB1的免疫效应分子RELMb,它介导了胃肠道线虫感染的排泄。调节RELMb表达的因素和驱除蠕虫的机制将被定义。定义这些途径将提供
对胃肠道固有和适应性Th2反应的调节有了新的见解,并为操纵抗线虫反应提供了新的靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Artis其他文献
David Artis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Artis', 18)}}的其他基金
Dietary Regulation of Intestinal Inflammation and Repair
肠道炎症和修复的饮食调节
- 批准号:
10592429 - 财政年份:2022
- 资助金额:
$ 36.86万 - 项目类别:
Microbiota-derived metabolites and the regulation of host immunity and inflammation
微生物群衍生的代谢物以及宿主免疫和炎症的调节
- 批准号:
10512805 - 财政年份:2022
- 资助金额:
$ 36.86万 - 项目类别:
Microbiota-derived metabolites and the regulation of host immunity and inflammation
微生物群衍生的代谢物以及宿主免疫和炎症的调节
- 批准号:
10645229 - 财政年份:2022
- 资助金额:
$ 36.86万 - 项目类别:
Neuro-immune regulation of intestinal inflammation
肠道炎症的神经免疫调节
- 批准号:
10670215 - 财政年份:2020
- 资助金额:
$ 36.86万 - 项目类别:
Neuropeptide-mediated regulation of antihelminth immunity
神经肽介导的抗蠕虫免疫调节
- 批准号:
10120198 - 财政年份:2020
- 资助金额:
$ 36.86万 - 项目类别:
Neuropeptide-mediated regulation of antihelminth immunity
神经肽介导的抗蠕虫免疫调节
- 批准号:
10468776 - 财政年份:2020
- 资助金额:
$ 36.86万 - 项目类别:
Neuro-immune regulation of intestinal inflammation
肠道炎症的神经免疫调节
- 批准号:
10462650 - 财政年份:2020
- 资助金额:
$ 36.86万 - 项目类别:
Neuropeptide-mediated regulation of antihelminth immunity
神经肽介导的抗蠕虫免疫调节
- 批准号:
10265558 - 财政年份:2020
- 资助金额:
$ 36.86万 - 项目类别:
Neuropeptide-mediated regulation of antihelminth immunity
神经肽介导的抗蠕虫免疫调节
- 批准号:
10681244 - 财政年份:2020
- 资助金额:
$ 36.86万 - 项目类别:
Neuro-immune regulation of intestinal inflammation
肠道炎症的神经免疫调节
- 批准号:
10097714 - 财政年份:2020
- 资助金额:
$ 36.86万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 36.86万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 36.86万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 36.86万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 36.86万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 36.86万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 36.86万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 36.86万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 36.86万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 36.86万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 36.86万 - 项目类别: